Abstract
Brachytherapy dose distributions are calculated for 15 mm ROPES eye plaque loaded with model Theragenics200 and IR06-103Pd seeds. The effects of stainless steel backing and Acrylic insert on dose distribution along the central axis of the eye plaque and at critical ocular structure are investigated. Monte Carlo simulation was carried out with the Version 5 of the MCNP. The dose at critical ocular structure by considering the eye composition was calculated. Results are compared with the calculated data for COMS eye plaque loaded with Theragenics200 palladium-103 seeds and model 6711 iodine-125 seed. The air kerma strength of the IR06-103Pd seed to deliver 85 Gy in apex of tumor in water medium was calculated to be 4.10 U/seed. Along the central axis of stainless steel plaque loaded with new 103Pd seeds in Acrylic insert, the dose reduction relative to water is 6.9% at 5 mm (apex). Removal of the Acrylic insert from the plaque (replacing with water) did not make significantly difference in dose reduction results (~0.2%). The presence of the stainless steel backing results in dose enhancement near the plaque relative to water. Doses at points of interest are higher for ROPES eye plaque when compared to COMS eye plaque. The dosimetric parameters calculated in this work for the new palladium seed, showed that in dosimetry point of view, the IR06-103Pd seed is suitable for use in brachytherapy. The effect of Acrylic insert on dose distribution is negligible and the main effect on dose reduction is due to the presence of stainless steel plaque backing.
Similar content being viewed by others
References
Grin-Jorgensen C, Berke A, Grin M (1992) Ocular melanoma. Dermatol Clin 10:663–668
Robertson DM (2003) Changing concepts in the management of choroidal melanoma. Am J Ophthalmol 136:161–170
Finger PT (1997) Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232
Nag S, Quivey J, Earle J, Followill D, Fontanesi J, Finger PT (2003) The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 56:544–555
Char DH, Kroll S, Quivey JM, Castro J (1996) Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy. Br J Ophthalmol 80:117–124
Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF et al (2001) Collaborative Ocular Melanoma Study (COMS) randomized trial of 125I brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Ophthalmology 108:348–366
Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM (2001) The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma. III: initial mortality findings COMS Report No. 18. Arch Ophthalmol 119:969–982
Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP et al (2002) The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy COMS report no. 19. Ophthalmology 109:2197–2206
Heikkone J, Summanen P, Immonen I, Tommila P, Toivola H, Forss M et al (1992) Radiotherapy of malignant melanoma of the uvea with I-125 seeds. Acta Ophthalmol (Copenh) 70:780–785
Robertson DM, Earle J, Anderson JA (1983) Preliminary observations regarding the use of iodine125 in the management of choroidal melanoma. Trans Ophthalmol Soc UK 103:155–160
Packer S, Rotman M (1980) Radiotherapy of choroidal melanoma with iodine-125. Int Ophtalmol Clin 20:135–142
Hall EJ, Brenner DJ (1991) The dose rate effect revisited: radiobiological considerations of importance in radiotherapy. Int J Radiat Oncol Biol Phys 21:1403–1414
Finger PT, Berson A, Szechter A (1999) Palladium-103 plaque radiotherapy for choroidal melanoma: results of a 7 years study. Ophthalmology 106:606–613
Finger PT, Moshfeghi DM, Ho TK (1991) Palladium-103 ophthalmic plaque radiotherapy. Arch Ophthalmol 109:1610–1613
Saidi P, Sadeghi M, Shirazi A, Tenreiro C (2010) Monte Carlo calculation of dosimetry parameters for the IR08–103Pd brachytherapy source. Med Phys 37:2509–2515
Cygler J, Szanto J, Soubra M (1990) Effect of gold and silver backing on the dose rate around and 125I seed. Med Phys 17:172–178
Wu A, Sternick ES, Muise DJ (1988) Effect of gold shielding on the dosimetry of an 125-I seed at close range. Med Phys 15:627–628
Luxton G, Astrahan MA, Petrovich Z (1988) Backscatter measurements from a single seed of 125I for ophthalmic plaque dosimetry. Med Phys 15:397–400
Thomson RM, Taylor REP, Rogers DWO (2008) Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy. Med Phys 35:5530–5543
Chiu-Tsao S, Anderson LL, O’Brien K, Stabile L, Liu JC (1993) Dosimetry for 125I seed (model 6711) in eye plaque. Med Phys 20:383–389
Weaver KA (1986) The dosimetry of 125I seed eye plaques. Med Phys 13:78–83
De la Zerda A, Chiu-Tsao S, Lin J, Boulay LL, Kanna I, Tsao H (1996) 125I plaque dose distribution including penumbra characteristics. Med Phys 23:407–418
Granero D, Perez-Calatayud J, Ballester F, Casal E (2004) Dosimetric study of the 15 mm ROPES eye plaque. Med Phys 31:3330–3336
Rivard MJ, Coursey BM, DeWerd LA, Hanson WF, Huq MS, Ibbott GS, Mitch MG, Nath R, Williamson JF (2004) Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys 31:633–674
Williamson JF (2000) Monte Carlo modeling of the transverse-axis dose distribution of the model 200 103Pd interstitial brachytherapy source. Med Phys 27:643–654
Thomson RM, Rogers DWO (2010) Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models. Med Phys 37:368–376
Monte Carlo Team, MCNP-A General Monte Carlo N-Particle Transport Code-Version 5, Los Alamos National Laboratory, http://mcnp-green.lanl.gov/index.html, (last reviewed 29-Jan-2004)
Sadeghi M, Raisali Gh, Hosseini SH, Shahvar A (2008) Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA-103Pd brachytherapy source. Med Phys 35:1288–1294
Melhus CS, Rivard MJ (2008) COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, 131Cs. Med Phys 35:3364–3371
Popescu CC, Wise J, Sowards K, Meigooni AS, Ibbott GS (2000) Dosimetric characteristic of the Pharma Seed model BT-125-I source. Med Phys 27:2174–2181
Kouwenhoven E, Laarse R, Schaart DR (2001) Variation in interpretation of the AAPM TG-43 geometry factor leads to unclearness in brachytherapy dosimetry. Med Phys 28:1965–1966
Meigooni AS, Bharucha Z, Yoe-Sein M, Sowards K (2001) Dosimetric characteristic of the best double–wall 103Pd brachytherapy source. Med Phys 28:2568–2575
Bearden JA, Burr AF (1967) Reevaluation of X-ray atomic energy levels. Rev Med Phys 39:125–142
ICRU (1992) Photon, Electron, Photon and Neutron Interaction Data for Body Tissues, ICRU Report 46. ICRU, Washington DC
Wallace RE, Fan JJ (1999) Dosimetric characterization of a new design 103palladium brachytherapy source. Med Phys 26:2465–2470
Li Z, Palta JR, Fan JJ (2000) Monte Carlo calculations and experimental measurements of dosimetry parameters of a new 103Pd source. Med Phys 27:1108–1112
Nath R, Yue N, Shahnazi K, Bongiorni PJ (2000) Measurement of dose-rate constant for 103Pd seeds with air kerma strength calibration based upon a primary national standard. Med Phys 27:655–658
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s13246-011-0094-0
Rights and permissions
About this article
Cite this article
Saidi, P., Sadeghi, M., Shirazi, A. et al. ROPES eye plaque brachytherapy dosimetry for two models of 103Pd seeds . Australas Phys Eng Sci Med 34, 223–231 (2011). https://doi.org/10.1007/s13246-011-0069-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13246-011-0069-1